Spleen Stiffness Measurement by Using Shear-Wave Elastography as a Predictor of Progression to Secondary Myelofibrosis.
Journal
Ultrasound quarterly
ISSN: 1536-0253
Titre abrégé: Ultrasound Q
Pays: United States
ID NLM: 8809459
Informations de publication
Date de publication:
01 Jun 2021
01 Jun 2021
Historique:
entrez:
31
5
2021
pubmed:
1
6
2021
medline:
29
10
2021
Statut:
ppublish
Résumé
Polycythemia vera (PV) and essential thrombocythemia (ET) are chronic myeloproliferative diseases that can transform to secondary myelofibrosis (SMF). In this study, we evaluated spleen stiffness using shear-wave elastography (SWE) as a predictor of progression to SMF. Participants were grouped as healthy volunteers (HVs), PV/ET patients, and SMF patients. Participants' spleen sizes, spleen stiffness values, bone marrow fibrosis degrees, and the other parameters were evaluated. Spleen stiffness values and spleen sizes were compared between groups. Of the 121 participants included in this study, 52 patients were HVs, 52 patients were PV and/or ET patients, and 17 patients were SMF patients. In terms of age and sex, there was no difference between groups. Splenic parenchymal stiffness median values by using SWE were found to be 0.82 m/s in HVs, 1.41 m/s in PV/ET patients, and 2.32 m/s in SMF patients (P < 0.001). In terms of median length of the spleen, the difference between groups was significant (P < 0.001). In addition, we found a significant positive correlation between spleen stiffness and bone marrow fibrosis degree (P < 0.001, r = 0.757). However, in multivariate analysis, there was no strong independent risk factor for spleen stiffness. In this study, we showed that measurement of spleen stiffness using SWE can distinguish SMF from PV/ET patients and HVs. Therefore, we believe that SWE may be used as a noninvasive and easily accessible method to check the fibrotic progression of bone marrow in PV and ET patients to monitor the transformation to SMF, and enables to detect fibrosis in early phase.
Identifiants
pubmed: 34057915
doi: 10.1097/RUQ.0000000000000486
pii: 00013644-202106000-00012
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
149-154Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interests, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.
Références
Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol . 2011;29:573–582.
Barbui T, Thiele J, Gisslinger H, et al. The 2016 revision of WHO classification of myeloproliferative neoplasms: clinical and molecular advances. Blood Rev . 2016;30(6):453–459.
Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome–negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia . 2018;32(5):1057–1069.
Srour SA, Devesa SS, Morton LM, et al. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001–12. Br J Haematol . 2016;174(3):382–396.
Szuber N, Mudireddy M, Nicolosi M, et al. 3023 Mayo Clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups. Mayo Clin Proc . 2019;94(4):599–610.
Barosi G, Mesa RA, Thiele J, et al., International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Proposed criteria for the diagnosis of post–polycythemia vera and post–essential thrombocythemia myelofibrosis: a consensus statement from the international working Group for Myelofibrosis Research and Treatment. Leukemia . 2008;22(2):437–438.
Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood . 2007;110(4):1092–1097.
Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica . 2005;90:1128–1132.
Gennisson JL, Deffieux T, Fink M, et al. Ultrasound elastography: principles and techniques. Diagn Interv Imaging . 2013;94(5):487–495.
Shiina T, Nightingale KR, Palmeri ML, et al. WFUMB guidelines and recommendations for clinical use of ultrasound elastography: part 1: basic principles and terminology. Ultrasound Med Biol . 2015;41(5):1126–1147.
Sigrist RMS, Liau J, Kaffas AE, et al. Ultrasound elastography: review of techniques and clinical applications. Theranostics . 2017;7(5):1303–1329.
Masarova L, Verstovsek S, Hidalgo-Lopez JE, et al. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood . 2018;132(16):1664–1674.
Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol . 2012;87(3):285–293.
Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: the Mayo Clinic experience. Mayo Clin Proc . 2012;87(1):25–33.
Tefferi A. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol . 2014;89(9):915–925.
Andrikovics H, Krahling T, Balassa K, et al. Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations. Haematologica . 2014;99(7):1184–1190.
Dietrich CF, Bamber J, Berzigotti A, et al. EFSUMB guidelines and recommendations on the clinical use of liver ultrasound elastography, update 2017 (long version). Ultraschall Med . 2017;38(4):e16–e47.
Ozgokce M, Durmaz F, Yavuz A, et al. Shear-wave elastography in the characterization of pleural effusions. Ultrasound Q . 2019;35(2):164–168.
Leung VY, Shen J, Wong VW, et al. Quantitative elastography of liver fibrosis and spleen stiffness in chronic hepatitis B carriers: comparison of shear-wave elastography and transient elastography with liver biopsy correlation. Radiology . 2013;269(3):910–918.
McKenzie CV, Colonne CK, Yeo JH, et al. Splenomegaly: pathophysiological bases and therapeutic options. Int J Biochem Cell Biol . 2018;94:40–43.
Batur A, Alagoz S, Durmaz F, et al. Measurement of spleen stiffness by shear-wave elastography for prediction of splenomegaly etiology. Ultrasound Q . 2019;35(2):153–156.
Webb M, Shibolet O, Halpern Z, et al. Assessment of liver and spleen stiffness in patients with myelofibrosis using FibroScan and shear wave elastography. Ultrasound Q . 2015;31(3):166–169.
Fraquelli M, Giunta M, Pozzi R, et al. Feasibility and reproducibility of spleen transient elastography and its role in combination with liver transient elastography for predicting the severity of chronic viral hepatitis. J Viral Hepat . 2014;21(2):90–98.
Iurlo A, Cattaneo D, Giunta M, et al. Transient elastography spleen stiffness measurements in primary myelofibrosis patients: a pilot study in a single Centre. Br J Haematol . 2015;170(6):890–892.